by David Wallace What does precision medicine look like in MPNs? Can it be used to diagnose, prognosticate and treat patients? Discover information on driver mutations, symptom burden scoring and how it is used in some clinical visits. Learn more as Dr. Naveen Pemmaraju, Associate Professor, Department of Leukemia, Division of Cancer Medicine, The University […]
New MPN Drug Treatments in Development
by David Wallace What are some of the latest combination drug treatments in development for MPN? Find out the latest on combination add-on strategies to JAK inhibitors and other new agents. Two combination therapies for Myelofibrosis look promising as they move into phase 3 clinical trials. They include adding CPI-0610 (a bromodomain, BET, inhibitor) and […]
Clinical Trial Update on Emerging MPN Treatments
by David Wallace Find out the latest news on Ropeginterferon and PTG-300 for treating polycythemia vera, as well as the most promising new treatments for myelofibrosis. What’s the clinical significance of the Allele Burden (AB)? Are there common elements between COVID-19 and MPN…should you get the vaccine? Learn more as Dr. Srdan Verstovsek, Professor, Department of […]
